LAUSR

Key Points Question Is extended-interval fixed dosing of pembrolizumab associated with increased health care costs? Findings This economic evaluation including simulated patients found that using the US Food and Drug Administration–labeled pembrolizumab dose of 400 mg every 6 weeks instead of 200 mg every 3 weeks may result in an estimated 8% increase in health care costs in the US. Meaning These findings suggest that when considering different dosing options, clinicians and policy makers should consider the potential impact on costs.